Pseudotumor cerebri

Zusammenfassung

Der Pseudotumor cerebri ist eine intrakranielle Liquordruckerhöhung, die entweder idiopathisch oder symptomatisch auftreten kann. Die Diagnose wird nach den Kriterien der International Headache Society gestellt. Zur Pathogenese der idiopathischen Form ist wenig bekannt. Risikofaktoren sind weibliches Geschlecht und Adipositas. Symptomatische Formen können durch Intoxikationen oder Formen des Hydrozephalus hervorgerufen werden. Die Therapie besteht bei symptomatischen Formen in der Behandlung der Grunderkrankung. Ansonsten sind eine Gewichtsreduktion und eine medikamentöse Behandlung mit Acetazolamid, Topiramat oder Furosemid sinnvoll. Operative Verfahren sind möglich, sollten aber nur als letzte Möglichkeit eingesetzt werden.

Summary

Pseudotumor cerebri is an intracranial increase of CSF pressure which can occur either as an idiopathic or as a symptomatic type. The diagnosis is made according to the criteria of the International Headache Society. The pathogenesis of the idiopathic type is poorly understood. Risk factors are female sex and obesity. Symptomatic types can be caused by intoxications or different types of hydrocephalus. The treatment of symptomatic types is primarily the treatment of the underlying disorder. Furthermore, weight reduction and drug treatment with acetazolamide, topiramate, or furosemide are helpful. Surgical procedures are possible but should be used only if all other possibilities have not been successful.

Schlüsselwörter

Pseudotumor cerebri - Hydrozephalus - Acetazolamid - Sinusthrombose

Keywords

Pseudotumor cerebri - hydrocephalus - acetazolamide - sinus thrombosis

• Literatur

• 1 Quincke H. Über Meningitis serosa: Sammlung Linische Vortra 67. Innere Medizin 1893; 23: 655-94.
• 2 Garrett J, Corbett J, Braswell R. The incidence of idiopathic intracranial hypertenion in Mississippi. North American Neuro-Ophthalmology Society 2004; 86.
• 3 Jacobs D, Corbett J, Balcer L. Annual incidence of idiopathic intracranial hypertension (IIH) in the Philadephia area. North American Neuro-Ophthalmology Society 2004; 286.
• 4 Radhakrishnan K. et al. Epidemiology of idiopathic intracranial hypertension: a prospective and casecontrol study. J Neurol Sci 1993; 116: 18-28.
• 5 Durcan FJ, Corbett JJ, Wall M. The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana. Arch Neurol 1988; 45: 875-7.
• 6 Dhungana S, Sharrack B, Woodroofe N. Idiopathic intracranial hypertension. Acta Neurol Scand 121: 71-82.
• 7 Headache Classification Committee. The International Classification of Headache Disorders. 2nd edition. Cephalalgia. 2004. 24 Suppl 1: 9-160.
• 8 Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002; 59: 1492-5.
• 9 Uddin AB. Drug-induced pseudotumor cerebri. Clin Neuropharmacol 2003; 26: 236-8.
• 10 Chiu AM. et al. Minocycline treatment and pseudotumor cerebri syndrome. Am J Ophthalmol 1998; 126: 116-21.
• 11 Gardner K, Cox T, Digre KB. Idiopathic intracranial hypertension associated with tetracycline use in fraternal twins: case reports and review. Neurology 1995; 45: 6-10.
• 12 Getenet JC. et al. Idiopathic intracranial hypertension after ofloxacin treatment. Acta Neurol Scand 1993; 87: 503-4.
• 13 Winrow AP, Supramaniam G. Benign intracranial hypertension after ciprofloxacin administration. Arch Dis Child 1990; 65: 1165-6.
• 14 Cohen DN. Intracranial hypertension and papilledema associated with nalidixic acid therapy. Am J Ophthalmol 1973; 76: 680-2.
• 15 Morrice G. Papilledema and hypervitaminosis A. Jama 1970; 213: 1344.
• 16 Roytman M, Frumkin A, Bohn TG. Pseudotumor cerebri caused by isotretinoin. Cutis 1988; 42: 399-400.
• 17 Walsh FB. et al. Oral contraceptives and neuroophthalmologic interest. Arch Ophthalmol 1965; 74: 628-40.
• 18 Neville BG, Wilson J. Benign intracranial hypertension following corticosteroid withdrawal in childhood. Br Med J 1970; 03: 554-6.
• 19 Hamed LM. et al. Pseudotumor cerebri induced by danazol. Am J Ophthalmol 1989; 107: 105-10.
• 20 Levine SH, Puchalski C. Pseudotumor cerebri associated with lithium therapy in two patients. J Clin Psychiatry 1990; 51: 251-3.
• 21 Saul RF, Hamburger HA, Selhorst JB. Pseudotumor cerebri secondary to lithium carbonate. Jama 1985; 253: 2869-70.
• 22 Konomi H. et al. Indomethacin causing pseudotumor cerebri in Bartter’s syndrome. N Engl J Med 1978; 298: 855.
• 23 Rogers AH. et al. Pseudotumor cerebri in children receiving recombinant human growth hormone. Ophthalmology 1999; 106: 1186-9.
• 24 Cruz OA, Fogg SG, Roper-Hall G. Pseudotumor cerebri associated with cyclosporine use. Am J Ophthalmol 1996; 122: 436-7.
• 25 Ahmad S. Amiodarone and reversible benign intracranial hypertension. Cardiology 1996; 87: 90.
• 26 Borruat FX, Regli F. Pseudotumor cerebri as a complication of amiodarone therapy. Am J Ophthalmol 1993; 116: 776-7.
• 27 Newborg B. Pseudotumor cerebri treated by rice reduction diet. Arch Intern Med 1974; 133: 802-7.
• 28 Liu GT, Volpe NJ, Galetta SL. Pseudotumor cerebri and its medical treatment. Drugs Today (Barc) 1998; 34: 563-74.
• 29 Alore PL, Jay WM, Macken MP. Topiramate, pseudotumor cerebri, weight-loss and glaucoma: an ophthalmologic perspective. Semin Ophthalmol 2006; 21: 15-7.
• 30 Palacio E, Rodero L, Pascual J. Topiramate-responsive headache due to idiopathic intracranial hypertension in Behcet syndrome. Headache 2004; 44: 436-7.
• 31 Markind JE. Topiramate: a new antiepileptic drug. Am J Health Syst Pharm 1998; 55: 554-62.
• 32 Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 1997; 19: 1294-308.
• 33 Schoeman JF. Childhood pseudotumor cerebri: clinical and intracranial pressure response to acetazolamide and furosemide treatment in a case series. J Child Neurol 1994; 09: 130-4.
• 34 Randhawa S, Van Stavern GP. Idiopathic intracranial hypertension (pseudotumor cerebri). Curr Opin Ophthalmol 2008; 19: 445-53.
• 35 Brazis PW. Clinical review: the surgical treatment of idiopathic pseudotumour cerebri (idiopathic intracranial hypertension). Cephalalgia 2008; 28: 1361-73.
• 36 Sugerman HJ. et al. Effects of surgically induced weight loss on idiopathic intracranial hypertension in morbid obesity. Neurology 1995; 45: 1655-9.
• 37 Sugerman HJ. et al. Gastric surgery for pseudotumor cerebri associated with severe obesity. Ann Surg 1999; 229: 634-40.
• 38 Owler BK. et al. Pseudotumor cerebri syndrome: venous sinus obstruction and its treatment with stent placement. J Neurosurg 2003; 98: 1045-55.
• 39 Rohr A. et al. Reversibility of venous sinus obstruction in idiopathic intracranial hypertension. AJNR Am J Neuroradiol 2007; 28: 656-9.
• 40 Donnet A. et al. Endovascular treatment of idiopathic intracranial hypertension: clinical and radiologic outcome of 10 consecutive patients. Neurology 2008; 70: 641-7.
• 41 Albuquerque FC. et al. Intracranial venous sinus stenting for benign intracranial hypertension: clinical indications, technique, and preliminary results. World Neurosurg 2011; 75: 648-52.
• 42 Riedel CH. et al. Subacute stent thrombosis in intracranial stenting. Stroke 2009; 40: 1310-4.
• 43 Friedman DI. Cerebral venous pressure, intra-abdominal pressure, and dural venous sinus stenting in idiopathic intracranial hypertension. J Neuroophthalmol 2006; 26: 61-4.
• 44 Corbett JJ, Mehta MP. Cerebrospinal fluid pressure in normal obese subjects and patients with pseudotumor cerebri. Neurology 1983; 33: 1386-8.
• 45 Wong R. et al. Idiopathic intracranial hypertension: the association between weight loss and the requirement for systemic treatment. BMC Ophthalmol 2007; 07: 15.
• 46 Evans RW, Friedman DI. Expert opinion: the management of pseudotumor cerebri during pregnancy. Headache 2000; 40: 495-7.